Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny. Compounding ...

Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor. Teva Pharmaceuticals International GmbH, a ...

Chad Hoskins is the CEO of Phagenesis and brings deep experience leading and building organizations to successfully bring innovative medical technologies to market. Before joining Phagenesis, he ...

Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the ...

Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior ...

Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real ...

The FDA today expanded the approval of Talzenna (talazoparib) plus Xtandi (enzalutamide) to men with metastatic prostate cancer that has not been treated with androgen pathway dru ...

Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.

Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year ...

One of the most discussed use cases in pharma and biotech for AI is the creation of digital twins. By using massive amounts ...

Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.

This episode of The Ron Lanton Report features Dr. Nadine Zawadzki, a pharmaceutical and health economist and senior director ...